From: Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis
 | Selection |  |  |  | Comparability | Outcome | Total score | ||
---|---|---|---|---|---|---|---|---|---|
Representative of exposed cohort | Selections of non exposed cohort | Assessment of exposure | Absence of outcome at start of study | Comparability | Assessment of outcome | Follow-up period (≥ 6 months) | Adequacy of follow-up | Out of 9 points | |
Bauer et al. 2016 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 (high) |
Bohnert et al. 2012 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 (high) |
Caudarella et al. 2016 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 (high) |
Dunn et al. 2010 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 (high) |
Hartung et al. 2007 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 (high) |
Seal et al. 2012 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 (high) |
Turner and Liang 2015 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 (high) |
 |  |  |  |  |  |  |  | mean | 8.1 |